News
Quantro and Boehringer Ingelheim collaborate on inhibitors
Quantro Therapeutics has announced that it has entered a three-year collaboration, option and licence agreement with Boehringer Ingelheim for the identification and development of inhibitors for up to three cancer-associated transcription factors.